These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors. Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320 [TBL] [Abstract][Full Text] [Related]
26. Separation of dopaminergic and serotonergic inhibitory mechanisms in the mediation of estrogen-induced lordosis behaviour in the rat. Fernández-Guasti A; Ahlenius S; Hjorth S; Larsson K Pharmacol Biochem Behav; 1987 May; 27(1):93-8. PubMed ID: 2956611 [TBL] [Abstract][Full Text] [Related]
28. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states. LaHoste GJ; Wigal T; King BH; Schuck SEB; Crinella FM; Swanson JM Exp Clin Psychopharmacol; 2000 Feb; 8(1):125-132. PubMed ID: 10743913 [TBL] [Abstract][Full Text] [Related]
29. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats]. Minematsu N Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718 [TBL] [Abstract][Full Text] [Related]
30. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment. Smith RC; Davis JM Psychopharmacol Commun; 1975; 1(3):285-93. PubMed ID: 1241453 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Ohno Y; Ishida K; Ikeda K; Ishibashi T; Okada K; Nakamura M Pharmacol Biochem Behav; 1994 Sep; 49(1):19-23. PubMed ID: 7816873 [TBL] [Abstract][Full Text] [Related]
32. Neuroleptic-induced reduction of quipazine-elicited head-twitches in rats: possible involvement of striatal dopaminergic supersensitivity. Dall'Olio R; Vaccheri A; Gandolfi O; Roncada P; Montanaro N Pharmacol Biochem Behav; 1988 Dec; 31(4):941-4. PubMed ID: 2908069 [TBL] [Abstract][Full Text] [Related]
33. Behavioural correlates of modified dopaminergic/anticholinergic responses following chronic treatment with neuroleptic agents of differing activity spectra. Costall B; Naylor RJ; Owen RT Eur J Pharmacol; 1978 Mar; 48(1):29-36. PubMed ID: 25189 [No Abstract] [Full Text] [Related]
34. The specificity of neuroleptic- and methysergide-induced behavioral hypersensitivity. Klawans HL; D'amico DJ; Nausieda PA; Weiner WJ Psychopharmacology (Berl); 1977 Nov; 55(1):49-52. PubMed ID: 414261 [No Abstract] [Full Text] [Related]
35. The effect of thioridazine on haloperidol induced behavioral hypersensitivity. Klawans HL; Carvey PM; Nelson D; Tanner CM; Goetz CG Life Sci; 1986 May; 38(19):1707-14. PubMed ID: 3702600 [TBL] [Abstract][Full Text] [Related]
36. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Naidu PS; Kulkarni SK Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040 [TBL] [Abstract][Full Text] [Related]